The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2017 | Reducing the neurotoxic side effects of adjuvant chemotherapy for colon cancer
Hendrik-Tobias Arkenau, MD, PhD of the Sarah Cannon Research Institute, Nashvile, TN, talks about a study presented at ASCO 2017 which investigated how long patients with stage III colon cancer need adjuvant chemotherapy. The current standard of care for patients with stage III colon cancer is adjuvant oxaliplatin based treatment for 6 months. However, the use of oxaliplatin can cause increase neurotoxicity, causing damage to the nerves of hand and feet. Therefore, this study (NCT01150045) aimed to answer the question of whether a shorter time of 3 months for oxaliplatin treatment is better than 6 months. Dr Arkenau explains that the study showed that oxaliplatin related neurotoxicity is reduced after 3 months as compared to 6 months.
Recorded at the American Society of Oncology (ASCO) 2017 Annual Meeting held in Chicago, IL
